Narcotic Drug Register: Rules for Storing and Selling Controlled Substances

Introduction

If you own or manage a retail pharmacy in India, the "narcotic drug register" usually comes up in one of two contexts: a Drug Inspector asking for it during a visit, or a supplier invoice for a codeine-based cough syrup that makes you wonder whether you're even allowed to stock it in the quantity you just ordered. Both questions trace back to the same law — the Narcotic Drugs and Psychotropic Substances Rules, 1985 (NDPS Rules) — but the details that actually matter to a pharmacy owner are easy to get wrong, because most summaries online blur together rules meant for doctors, hospitals, and commercial chemists as if they were one identical obligation.

This guide is written specifically for pharmacy owners, not doctors or hospital administrators, and focuses on the parts of Chapters VA and VB of the NDPS Rules that determine what you can stock, what licence you need, and which records actually apply to a retail counter versus a hospital pharmacy. For related requirements, see Schedule X Drugs: Rules Every Pharmacist Must Know and the broader Pharmacy Drug Licensing & Compliance in India guide.

What Is a Narcotic Drug Register?

That distinction is the reason two pharmacists can describe "the narcotic register" completely differently and both be right. A hospital pharmacy attached to a recognised medical institution really does keep named statutory forms. An independent retail chemist keeps records whose content is set by licence conditions and the Drugs and Cosmetics Rules, 1945 — not by Form 3D. Getting this backwards is what leads a retail pharmacy to maintain a form it was never required to keep, while leaving the records it actually owes incomplete.

In practice, the records a retail chemist is expected to produce for controlled stock come from Rule 65 of the Drugs and Cosmetics Rules, 1945. Between them they cover:

• Purchase records: The date of purchase, the name and address of the supplier and their licence number, the name of the drug, the quantity, the batch number, and the manufacturer — Rule 65(4)(4)(i).
• The prescription register: A serial number for each entry, the date of supply, the prescriber's name and address, the patient's name and address, the drug and quantity supplied, and the signature of the Registered Pharmacist who supplied it — Rule 65(3). The serial number is written back onto the prescription itself.
• The Schedule H1 register: A separate register recording the prescriber's name and address, the patient's name, the drug, and the quantity supplied — retained for three years and open to inspection, under Rule 65(3)(h).
• Schedule X records: Their own licence (Forms 20-F/21-F), locked storage, and a copy of the prescription retained for two years — a separate track again, covered in the Schedule X guide.

Four practical points follow from this that generic checklists tend to miss. First, retention periods are not uniform: the Schedule H1 register runs three years, Schedule X prescription copies two years, and the Rule 52H practitioner and institutional forms two years from the date of the last entry — so a single "keep everything for two years" policy under-retains the H1 register.

Second, Chapter VA of the NDPS Rules — Rules 52A to 52M, inserted in 2015 — imposes no separate safe-custody or lock-and-key requirement on a licenced chemist. Physical security for controlled stock comes from your licence conditions and, for Schedule X items, from the Drugs and Cosmetics Rules. Third, expired stock is dealt with under Rule 52M, which requires expired essential narcotic drugs held by an authorised person or a registered medical practitioner to be destroyed in the manner specified by the Controller of Drugs — so destruction is not something to handle quietly in-house without checking your state's procedure.

Fourth, state Drug Controllers routinely prescribe their own register formats and inspection expectations on top of this central baseline, so the layout your neighbouring state uses may not be the one your inspector expects. And whatever format you use, keep NDPS-relevant stock out of a single undifferentiated register shared with ordinary Schedule H and H1 lines — a co-mingled ledger makes it far harder to demonstrate the balance for a specific controlled item on a specific date, which is precisely what gets asked for.

Who Does the Rule 52A Possession Table Actually Apply To?

The Rule 52A quantity table binds registered medical practitioners only. It caps what a doctor may personally hold for use in their own practice, and Rule 52A(3) says so in terms — "but not for sale or distribution". It is not a general possession ceiling for anyone handling essential narcotic drugs, and it does not cap a pharmacy's commercial stock. Most online summaries reproduce the figures — 500mg morphine, 2,000mg codeine, and so on — without that qualifier, which is where the misreading starts.

"A registered medical practitioner may possess essential narcotic drug, for use in his practice but not for sale or distribution, not more than the quantity mentioned in the Table below."

The Rule 52A(3) table is a ceiling on what a doctor may personally hold for administering to patients in their own clinical practice — it has nothing to do with how much a pharmacy can legally stock for sale. Where a practitioner genuinely needs more, Rule 52A(3) also lets the Controller of Drugs authorise a larger quantity by special order in Form 3B.

A licenced chemist's possession limit for essential narcotic drugs is instead governed by the specific conditions attached to their commercial licence under Rule 52B (covered below) — not by this table. Treating the Rule 52A figures as "how much my pharmacy can legally hold" is a genuine and consequential misreading of the rule.

Separately, Rule 52A(2) allows any person (i.e., a patient) to possess whatever quantity of an essential narcotic drug has been lawfully sold or dispensed to them for their own use — this is the general public possession allowance, again distinct from a pharmacy's commercial stock.

"Any person may possess an essential narcotic drug in such quantity as has been at one time sold or dispensed for his use in accordance with the provisions of these rules."

What Counts as an "Essential Narcotic Drug"?

The officially notified list of Essential Narcotic Drugs (ENDs), created by the 2014 amendment to the NDPS Act and given uniform nationwide rules in 2015, consists of six drugs, not five:

Methadone was added to the END list via the 2014 amendment specifically to support opioid substitution therapy, but the Rule 52A table — as consolidated in the current Rules — does not assign it a default practitioner threshold the way it does for the other five. Again, remember: this entire table describes RMP practice-use limits, not pharmacy stock limits.

Does the Codeine Exemption Apply to My Cough Syrup Stock?

Most codeine-based cough and cold preparations are exempt from the 2,000 milligramme threshold in the Rule 52A table. The exemption is not a general one for cough syrup — it is a set of four cumulative conditions, and a preparation has to meet all of them. The Rules exempt codeine and ethylmorphine preparations that are:

• Compounded with one or more other ingredients (i.e., not raw or pure codeine), and
• Containing not more than 100 milligrammes of the drug per dosage unit, and
• At a concentration of not more than 2.5% in undivided preparations, and
• Established in therapeutic practice.

Most standard codeine-based cough syrups sold in Indian pharmacies are formulated specifically to fall within this exemption — a typical 10mg-per-5ml syrup sits at roughly 0.2% concentration, well inside both limits. This does not mean these products are unregulated: they remain subject to Schedule H requirements, prescription rules, and — as covered next — commercial-quantity risk under the NDPS Act if held in bulk. It means they are not treated as an "essential narcotic drug" possession issue under Rule 52A's strict threshold in the same way pure morphine or oxycodone would be.

The "Commercial Quantity" Trap: Total Weight, Not Just Drug Content

Even where a specific formulation falls outside Rule 52A's possession table, a separate and more serious risk exists under the main NDPS Act's offence provisions (Section 21 and the related quantity notification): the concept of "commercial quantity".

For years, courts calculated small and commercial quantity thresholds based only on the pure narcotic content of a seized substance — E. Micheal Raj v. Intelligence Officer, Narcotic Control Bureau, (2008) 5 SCC 161, decided 11 March 2008. That changed with the Supreme Court's 2020 ruling in Hira Singh & Anr. v. Union of India & Anr. A three-judge bench overturned E. Micheal Raj and upheld the government's position that where a narcotic drug is mixed with neutral substances — including the water, sugar, and excipients in a cough syrup — the entire weight of the mixture counts toward the small, intermediate, or commercial quantity classification, not just the pure drug content.

For a pharmacy, the practical implication is significant: a large stock of codeine-based cough syrup — even a formulation that qualifies for the Rule 52A possession exemption above — could still be measured by its total bottled weight if it becomes the subject of an NDPS Act inquiry, potentially pushing an otherwise routine inventory holding into "commercial quantity" territory, which carries materially harsher, non-bailable consequences under the Act.

The correctness of Hira Singh has itself been challenged. On 1 September 2025 a bench of Justices M. M. Sundresh and N. K. Singh issued notice in Mayank Girishbhai Shah v. Union of India, a petition seeking its reconsideration, and sought responses from the Union Government and the Narcotics Control Bureau. Treat this as an active, evolving area and check the current position with a legal professional rather than relying solely on the 2020 ruling.

Do I Need a Separate Licence to Stock Essential Narcotic Drugs?

Yes. A standard retail or wholesale drug licence does not cover essential narcotic drugs on its own. Under Rule 52B, a licenced dealer or licenced chemist must apply separately for a licence to possess, sell, exhibit, or distribute — by retail or wholesale — essential narcotic drugs, through the same authority that issues manufactured-drug retail and wholesale licences under the relevant State Government's Section 10 rules. This licence:

• Is separate from a standard retail or wholesale drug licence, even though the same authority typically issues both.
• Carries the same conditions as apply to a manufactured-drugs retail or wholesale licence under the State's Section 10 rules.
• Is where a chemist's actual possession limits for essential narcotic drugs are defined — not the Rule 52A practitioner table.

On transition timelines, two separate provisions matter, and they are frequently confused with each other:

• Section 76 of the NDPS Act: The rule-making power provision includes a savings clause: where a State Government had already granted a licence or permit for an essential narcotic drug under Section 10 before the 2014 Amendment Act commenced, that existing licence continued to be valid until its own expiry date, or for twelve months from the commencement of the 2014 Amendment, whichever was earlier.
• Rule 52B(4) of the 2015 Rules: Separately states that the new dedicated licence required under Rule 52B must be obtained within 180 days from the commencement of those Rules.

"The licence under this rule shall be obtained within a period of one hundred and eighty days from the date of commencement of these rules."

Section 76 and Rule 52B(4) aren't contradictory — they address two different moments. Section 76 governs how long an old state licence remained valid after the 2014 Act amendment, while Rule 52B(4) set the deadline for obtaining the new licence once the 2015 Rules came into force shortly after. Both are now historical deadlines from a compliance-planning perspective, but understanding both matters if you're ever verifying whether a long-standing licence arrangement was properly transitioned at the time.

Sale Rules: Who a Chemist Can Buy From and Sell To

Rule 52F restricts who a manufacturer or licenced dealer may sell essential narcotic drugs to, other than on prescription: another manufacturer, a licenced dealer, a licenced chemist, a registered medical practitioner, a person specifically authorised by the Controller of Drugs, or a recognised medical institution.

A licenced chemist may only sell an essential narcotic drug on a valid prescription, and this sale remains subject to the Drugs and Cosmetics Rules, 1945 as well — meaning your existing Schedule H and H1 prescription and invoicing discipline still applies on top of these NDPS-specific rules.

Prescription Requirements to Verify Before Dispensing (Rule 52G)

Before dispensing, a compliant prescription for an essential narcotic drug must meet the four conditions in Rule 52G. It must be:

• In writing, dated, and signed by the practitioner, with their full name, address, and registration number.
• Addressed to a named patient, with their name and address specified.
• Specific about the total quantity, daily dose, and period of consumption — for a patent or proprietary medicine, the quantity and strength alone is sufficient.
• Never issued by a practitioner for their own use — this is explicitly prohibited.

Which Narcotic Records Must a Retail Pharmacy Actually Keep?

A retail chemist does not maintain Form 3D or Form 3E. Rule 52H's Form 3D and Form 3E obligations apply to registered medical practitioners and NDPS-authorised individuals — such as those in charge of an ambulance, first-aid station, or educational or research institution — not to a retail chemist's commercial ledger. A licenced chemist's recordkeeping duty instead flows from the conditions of their Rule 52B licence, which mirror the standard manufactured-drug retail and wholesale recordkeeping requirements: purchase invoices, sales records, and prescription retention.

Where Forms 3D and 3E — and additionally Forms 3H and 3-I — become directly relevant is for Recognised Medical Institutions (RMIs), such as hospitals and their attached pharmacies, under Chapter VB of the Rules:

• Form No. 3E (Rule 52R): A separate record for each patient, preserved for a minimum of two years from the date of the last entry.
• Form No. 3H (Rule 52R): A record of all receipts and disbursements of essential narcotic drugs for the institution as a whole, also preserved for a minimum of two years.
• Form No. 3-I (Rule 52R): An annual return for the calendar year, filed with the Controller of Drugs on or before the 31st of March of the following year.
• Form No. 3J (Rule 52T): An estimate of the institution's annual essential-narcotic-drug requirement, submitted by the 30th of November of the preceding year, with a revised estimate due by the 31st of August if actual need exceeds the original estimate.

If you run or supply a hospital pharmacy operating as a Recognised Medical Institution, telling your team that Form 3D and 3E alone cover your obligations is incomplete and could leave real compliance gaps — Form 3H and the annual Form 3-I return are separate, additional requirements specific to that institutional setting.

Retail Chemist vs Practitioner vs Recognised Medical Institution

Common Compliance Mistakes

• Reading the Rule 52A table as a pharmacy stock limit: It governs a practitioner's personal-practice possession, not commercial chemist stock — which is instead governed by your Rule 52B licence conditions.
• Assuming every codeine cough syrup is regulated at the 2,000mg threshold: Most compounded, low-concentration formulations are exempt from that specific table, though they remain subject to Schedule H and commercial-quantity risk.
• Ignoring total mixture weight when assessing bulk stock risk: Post-Hira Singh, the entire weight of a diluted product, not just its narcotic content, can determine commercial-quantity classification.
• Assuming a standard retail drug licence covers essential narcotic drugs: It doesn't, without the separate Rule 52B authorisation.
• Applying Form 3D and 3E requirements to a retail chemist: They are specifically written for registered medical practitioners and NDPS-authorised individuals.
• Telling a hospital pharmacy that Form 3D and 3E is sufficient: Recognised Medical Institutions also need Form 3H for receipts and disbursements, plus the annual Form 3-I return.

How BitMed Supports Controlled-Substance Recordkeeping

BitMed's product master flags drug schedule classifications on each medicine record, helping a pharmacy identify restricted and controlled items correctly rather than relying on staff to recognise them manually. Combined with BitMed's secure, cloud-backed recordkeeping and batch-wise inventory tracking, this supports the underlying discipline every one of these obligations depends on — accurate, retrievable purchase and sale records tied to the correct product.

It's worth being precise about scope: the specific licence conditions under Rule 52B, and the Form 3D/3E/3H/3-I requirements under Rules 52H and 52R, are statutory obligations tied to your licence type and role — retail chemist, practitioner, or recognised medical institution. BitMed supports the surrounding inventory and billing accuracy these records depend on, but does not substitute for maintaining the exact statutory forms your licence and role require.

Frequently Asked Questions

Conclusion

The single biggest source of confusion around the "narcotic drug register" is treating every essential-narcotic-drug rule as if it applies equally to doctors, hospitals, and pharmacies. It doesn't. The Rule 52A quantity table is about a practitioner's personal practice use, not your shop's stock room. Your pharmacy's actual possession limits and recordkeeping obligations come from your Rule 52B licence conditions. Forms 3D and 3E belong to practitioners; Forms 3H and 3-I belong to recognised institutions like hospitals.

And separately from all of this, the Supreme Court's Hira Singh ruling means bulk stock of even an exempted, diluted codeine formulation carries real commercial-quantity risk based on total weight — a detail worth discussing with a legal professional if your pharmacy carries volume stock of these products. For the wider compliance picture, including drug licensing categories, GST, and general recordkeeping, see the pillar guide to pharmacy licensing and compliance in India; for the locked-storage and bound-register regime that governs the other strictly controlled retail category, see the guide to Schedule X licensing and recordkeeping.

This guide summarises the NDPS Rules, 1985 as they stand for general information and is not legal advice. Rule references, forms, and quantity thresholds are subject to amendment and to state-level variation — confirm the current position with your State Drug Control Authority or a legal professional before acting on it.